Daina Graybosch, a top life science research analyst at SVB Leerink covering Immuno-Oncology, recently communicated to investors that Pfizer and partner BioNTech was moving forward with a Phase 1 clinical trial for a fifth candidate in the partnership’s COVID-19 vaccine portfolio known as BNT162. The partnership, of course, has progressed BNT162b2 to Phase 2/3 clinical testing but now is also progressing to clinicals a new vaccine known as BNT162b3. Obviously, the duo have identified significant promise for this candidate to proceed at this point to a Phase 1 clinical trial expected to commence in September. Interestingly, although Pfizer promoted BNT162b2 progression via the press, they have kept quiet about BNT162b3, opting not to issue a press release. Ms. Graybosch perhaps suggests Pfizer playing a longer strategic game to dominate the COVID-19 vaccine market with the mRNA-based technology partner BioNTech. Often it’s the “Vaccine 2.0” that becomes the standard.
After all, the first wave of vaccines have been rushed through at unprecedented speeds. Many experts suggest that the first batch of approved products won’t be the last as the science and research com...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).